Mavacamten: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Mavacamten. Educational only — not medical advice.
Labeled uses
CAMZYOS® is indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.
Source: FDA labeling via NIH DailyMed (set 669c936b…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.